Status
Conditions
Treatments
About
The purpose of this study is to obtain clinical outcome data on safety and effectiveness of the directSTIM DBS system when used on-label, according to the instructions for use.
All participants will undergo bilateral implant in the subthalamic nucleus (STN) and data collected in common practice will be recorded during six months post-implant and analyzed.
Full description
directSTIM DBS Therapy for Movement Disorders is indicated for patients with disabling tremor or symptoms of Parkinson's disease.
Subjects selected to participate in the study will be Parkinson's Disease (PD) patients who are eligible for bilateral DBS for STN therapy and meet the inclusion criteria and none of the exclusion criteria.
Primary safety and effectiveness endpoints data will be collected through 6 months of follow-up. The values used for comparison are derived from a review of literature spanning from 2001 to 2019.
After completing the 6 month follow-up, subject will exit the study, and continue to be followed by their physician per usual care.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patient is not eligible for DBS per center criteria.
Patient has a cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to complete study assessments, such as:
Patient is participating in another clinical study that would confound data analysis.
Patient is pregnant or nursing. As for other DBS systems, the effects of the device on an unborn child are not established.
Primary purpose
Allocation
Interventional model
Masking
62 participants in 1 patient group
Loading...
Central trial contact
Alain Dransart; Matthias Möhlmann, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal